The decision to pull Zinbryta followed cases of encephalitis, inflammation of the brain, and meningoencephalitis, which simultaneously resembles meningitis and encephalitis.
Biogen (BIIB) and AbbVie (ABBV) have announced they are pulling their jointly developed multiple sclerosis drug Zinbryta from the market following reports of brain inflammation in patients using the medication.
However, Biogen will not have much material impact because of this decision as Zinbryta was expected to bring in about $400 million in 2027 revenue for the company, or less than 3% of total sales. Biogen has a suite of multiple sclerosis drugs.
Zinbryta is tied to liver toxicity, inflammatory/immune toxicity and cases of hypersensitivity. The decision to pull Zinbryta followed cases of encephalitis, inflammation of the brain, and meningoencephalitis, which simultaneously resembles meningitis and encephalitis.
Biogen (BIIB) and AbbVie (ABBV) have announced they are pulling their jointly developed multiple sclerosis drug Zinbryta from the market following reports of brain inflammation in patients using the medication.
However, Biogen will not have much material impact because of this decision as Zinbryta was expected to bring in about $400 million in 2027 revenue for the company, or less than 3% of total sales. Biogen has a suite of multiple sclerosis drugs.
Zinbryta is tied to liver toxicity, inflammatory/immune toxicity and cases of hypersensitivity. The decision to pull Zinbryta followed cases of encephalitis, inflammation of the brain, and meningoencephalitis, which simultaneously resembles meningitis and encephalitis.
